Novel thioredoxin inhibitors paradoxically increase hypoxia-inducible factor-α expression but decrease functional transcriptional activity, DNA binding, and degradation

Clinical Cancer Research

Volumn 12, Issue 18, 2006, Pages 5384-5394

  Jones, Dylan T ^a   Pugh, Christopher W ^b   Wigfield, Simon ^a   Stevens, Malcolm F G ^c   Harris, Adrian L ^a  

^a UNIVERSITY OF OXFORD   (United Kingdom)

^b UNIVERSITY OF OXFORD   (United Kingdom)

^c UNIVERSITY OF NOTTINGHAM   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

AJM 290; ANTINEOPLASTIC AGENT; AW 464; BENZYLOXYCARBONYLLEUCYLLEUCYLLEUCINAL; CARBONATE DEHYDRATASE IX; HYPOXIA INDUCIBLE FACTOR 1ALPHA; HYPOXIA INDUCIBLE FACTOR 2ALPHA; LUCIFERASE; PROTEASOME INHIBITOR; PROTEIN BNIP3; PROTEIN INHIBITOR; QUINOLS; THIOREDOXIN; THIOREDOXIN INHIBITOR; UNCLASSIFIED DRUG; VASCULOTROPIN;

ARTICLE; BREAST CANCER; CANCER CELL CULTURE; CELL VIABILITY; CONCENTRATION RESPONSE; CONTROLLED STUDY; DNA BINDING; DRUG MECHANISM; DRUG STRUCTURE; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; HYPOXIA; KIDNEY CARCINOMA; PRIORITY JOURNAL; PROTEIN DEGRADATION; PROTEIN EXPRESSION; TRANSCRIPTION INITIATION; UPREGULATION;

ANTINEOPLASTIC AGENTS; BASIC HELIX-LOOP-HELIX TRANSCRIPTION FACTORS; BENZOTHIAZOLES; CELL SURVIVAL; CYCLOHEXANONES; DNA-BINDING PROTEINS; HUMANS; HYPOXIA-INDUCIBLE FACTOR 1; HYPOXIA-INDUCIBLE FACTOR 1, ALPHA SUBUNIT; INDOLES; LEUPEPTINS; MODELS, BIOLOGICAL; MUTANT PROTEINS; PROTEIN DENATURATION; RECOMBINANT PROTEINS; RESPONSE ELEMENTS; SULFONES; THIOREDOXIN; THIOREDOXINS; TRANS-ACTIVATION (GENETICS); TRANSCRIPTION FACTORS; TRANSCRIPTIONAL ACTIVATION; TUMOR CELLS, CULTURED; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 33749318557     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-05-2380     Document Type: Article

References (51)

1. Maxwell PH, Dachs GU, Gleadle JM, et al. Hypoxia-inducible factor-1 modulates gene expression in solid tumors and influences both angiogenesis and tumor growth. Proc Natl Acad Sci U S A 1997;94:8104-9.
2. 2 tension. Proc Natl Acad Sci U S A 1995;92:5510-4.
3. Wood SM, Gleadle JM, Pugh CW, Hankinson O, Ratcliffe PJ. The role of the aryl hydrocarbon receptor nuclear translocator (ARNT) in hypoxic induction of gene expression. Studies in ARNT-deficient cells. J Biol Chem 1996;271:15117-23.
4. Maxwell PH, Pugh CW, Ratcliffe PJ. The pVHL-hIF-1 system. A key mediator of oxygen homeostasis. Adv Exp Med Biol 2001;502:365-76.
5. 2-regulated prolyl hydroxylation. Science 2001;292:468-72.
6. Ema M, Hirota K, Mimura J, et al. Molecular mechanisms of transcription activation by HLF and HIF1α in response to hypoxia: their stabilization and redox signal-induced interaction with CBP/p300. EMBO J 1999;18:1905-14.
7. Minchenko A, Salceda S, Bauer T, Caro J. Hypoxia regulatory elements of the human vascular endothelial growth factor gene. Cell Mol Biol Res 1994;40:35-9.
8. Blancher C, Moore JW, Talks KL, Houlbrook S, Harris AL. Relationship of hypoxia-inducible factor (HIF)-1α and HIF-2α expression to vascular endothelial growth factor induction and hypoxia survival in human breast cancer cell lines. Cancer Res 2000;60:7106-13.
9. Semenza GL. Hypoxia, clonal selection, and the role of HIF-1 in tumor progression. Crit Rev Biochem Mol Biol 2000;35:71-103.
10. Bos R, Zhong H, Hanrahan CF, et al. Levels of hypoxia-inducible factor-1α during breast carcinogenesis. J Natl Cancer Inst 2001;93:309-14.
11. Laughner E, Taghavi P, Chiles K, Mahon PC, Semenza GL. HER2 (neu) signaling increases the rate of hypoxia-inducible factor 1α (HIF-1α) synthesis: novel mechanism for HIF-1-mediated vascular endothelial growth factor expression. Mol Cell Biol 2001; 21:3995-4004.
12. Zhong H, Chiles K, Feldser D, et al. Modulation of hypoxia-inducible factor 1α expression by the epidermal growth factor/phosphatidylinositol 3-kinase/PTEN/AKT/FRAP pathway in human prostate cancer cells: implications for tumor angiogenesis and therapeutics. Cancer Res 2000;60:1541-5.
13. Chen C, Pore N, Behrooz A, Ismail-Beigi F, Maity A. Regulation of glut1 mRNA by hypoxia-inducible factor-1. Interaction between H-ras and hypoxia. J Biol Chem 2001;276:9519-25.
14. Jiang BH, Agani F, Passaniti A, Semenza GL. V-SRC induces expression of hypoxia-inducible factor 1 (HIF-1) and transcription of genes encoding vascular endothelial growth factor and enolase 1: involvement of HIF-1 in tumor progression. Cancer Res 1997;57:5328-35.
15. Ravi R, Mookerjee B, Bhujwalla ZM, et al. Regulation of tumor angiogenesis by p53-induced degradation of hypoxia-inducible factor 1α. Genes Dev 2000;14:34-44.
16. Powis G, Kirkpatrick L. Hypoxia inducible factor-1α as a cancer drug target. Mol Cancer Ther 2004;3:647-54.
17. Semenza GL. Targeting HIF-1 for cancer therapy. Nat Rev Cancer 2003;3:721-32.
18. Yeo EJ, Chun YS, Cho YS, et al. YC-1: a potential anticancer drug targeting hypoxia-inducible factor 1. J Natl Cancer Inst 2003;95:516-25.
19. Powis G, Mustacich D, Coon A. The role of the redox protein thioredoxin in cell growth and cancer. Free Radic Biol Med 2000;29:312-22.
20. Saitoh M, Nishitoh H, Fujii M, et al. Mammalian thioredoxin is a direct inhibitor of apoptosis signal-regulating kinase (ASK) 1. EMBO J 1998;17:2596-606.
21. Watson JA, Rumsby MG, Wolowacz RG. Phage display identifies thioredoxin and superoxide dismutase as novel protein kinase C-interacting proteins: thioredoxin inhibits protein kinase C-mediated phosphorylation of histone. Biochem J 1999;343 Pt 2:301-5.
22. Hayashi T, Ueno Y, Okamoto T. Oxidoreductive regulation of nuclear factor κB. Involvement of a cellular reducing catalyst thioredoxin. J Biol Chem 1993;268:11380-8.
23. Ueno M, Masutani H, Arai RJ, et al. Thioredoxin-dependent redox regulation of p53-mediated p21 activation. J Biol Chem 1999;274:35809-15.
24. Welsh SJ, Bellamy WT, Briehl MM, Powis G. The redox protein thioredoxin-1 (Trx-1) increases hypoxia-inducible factor 1α protein expression: Trx-1 overexpression results in increased vascular endothelial growth factor production and enhanced tumor angiogenesis. Cancer Res 2002;62:5089-95.
25. Baker A, Payne CM, Briehl MM, Powis G. Thioredoxin, a gene found overexpressed in human cancer, inhibits apoptosis in vitro and in vivo. Cancer Res 1997;57:5162-7.
26. Gasdaska PY, Oblong JE, Cotgreave IA, Powis G. The predicted amino acid sequence of human thioredoxin is identical to that of the autocrine growth factor human adult T-cell derived factor (ADF): thioredoxin mRNA is elevated in some human tumors. Biochim Biophys Acta 1994;1218:292-6.
27. Raffel J, Bhattacharyya AK, Gallegos A, et al. Increased expression of thioredoxin-1 in human colorectal cancer is associated with decreased patient survival. J Lab Clin Med 2003;142:46-51.
28. Berggren M, Gallegos A, Gasdaska JR, Gasdaska PY, Warneke J, Powis G. Thioredoxin and thioredoxin reductase gene expression in human tumors and cell lines, and the effects of serum stimulation and hypoxia. Anticancer Res 1996;16:3459-66.
29. Grogan TM, Fenoglio-Prieser C, Zeheb R, et al. Thioredoxin, a putative oncogene product, is overexpressed in gastric carcinoma and associated with increased proliferation and increased cell survival. Hum Pathol 2000;31:475-81.
30. Nakamura H, Bai J, Nishinaka Y, et al. Expression of thioredoxin and glutaredoxin, redox-regulating proteins, in pancreatic cancer. Cancer Detect Prev 2000; 24:53-60.
31. Welsh SJ, Williams RR, Birmingham A, Newman DJ, Kirkpatrick DL, Powis G. The thioredoxin redox inhibitors 1-methylpropyl 2-imidazolyl disulfide and pleurotin inhibit hypoxia-induced factor 1α and vascular endothelial growth factor formation. Mol Cancer Ther 2003;2:235-43.
32. Welsh S, Williams R, Kirkpatrick L, Paine-Murrieta G, Powis G. Antitumor activity and pharmacodynamic properties of PX-478, an inhibitor of hypoxia-inducible factor-1α. Mol Cancer Ther 2004;3:233-44.
33. Wells G, Berry JM, Bradshaw TD, et al. 4-Substituted 4-hydroxycyclohexa- 2,5-dien-1-ones with selective activities against colon and renal cancer cell lines. J Med Chem 2003;46:532-41.
34. Wells G, Bradshaw TD, Diana P, et al. Antitumour benzothiazoles. Part 10. The synthesis and antitumour activity of benzothiazole substituted quinol derivatives. Bioorg Med Chem Lett 2000;10:513-5.
35. Mukherjee A, Westwell AD, Bradshaw TD, et al. Cytotoxic and antiangiogenic activity of AW464 (NSC 706704), a novel thioredoxin inhibitor: an in vitro study. Br J Cancer 2005;92:350-8.
36. Bradshaw TD, Matthews CS, Cookson J, et al. Elucidation of thioredoxin as a molecular target for antitumor quinols. Cancer Res 2005;65:3911-9.
37. Chomczynski P, Sacchi N. Single-step method of RNA isolation by acid guanidinium thiocyanate-phenol-chloroform extraction. Anal Biochem 1987; 162:156-9.
38. Pfaffl MW. A new mathematical model for relative quantification in real-time RT-PCR. Nucleic Acids Res 2001;29:e45.
39. O'Rourke JF, Tian YM, Ratcliffe PJ, Pugh CW. Oxygen-regulated and transactivating domains in endothelial PAS protein 1: comparison with hypoxia-inducible factor-1α. J Biol Chem 1999;274:2060-71.
40. Raval RR, Lau KW, Tran MG, et al. Contrasting properties of hypoxia-inducible factor 1 (HIF-1) and HIF-2 in von Hippel-Lindau-associated renal cell carcinoma. Mol Cell Biol 2005;25:5675-86.
41. Pallis M, Bradshaw TD, Westwell AD, et al. Induction of apoptosis without redox catastrophe by thioredoxin-inhibitory compounds. Biochem Pharmacol 2003;66:1695-705.
42. Berry JM, Bradshaw TD, Fichtner I, et al. Quinols as novel therapeutic agents. 2.(1) 4-(1-Arylsulfonylindol-2-yl)-4-hydroxycyclohexa-2,5-dien-1-ones and related agents as potent and selective antitumor agents. J Med Chem 2005;48:639-44.
43. Kirkpatrick DL, Kuperus M, Dowdeswell M, et al. Mechanisms of inhibition of the thioredoxin growth factor system by antitumor 2-imidazolyl disulfides. Biochem Pharmacol 1998;55:987-94.
44. Carrero P, Okamoto K, Coumailleau P, et al. Redox-regulated recruitment of the transcriptional coactivators CREB-binding protein and SRC-1 to hypoxia-inducible factor 1α. Mol Cell Biol 2000;20:402-15.
45. Huang LE, Arany Z, Livingston OM, Bunn HF. Activation of hypoxia-inducible transcription factor depends primarily upon redox-sensitive stabilization of its α subunit. J Biol Chem 1996;271:32253-9.
46. Barzilay G, Walker LJ, Rothwell DG, Hickson ID. Role of the HAP1 protein in repair of oxidative DNA damage and regulation of transcription factors. Br J Cancer Suppl 1996;27:S145-50.
47. Hirota K, Matsui M, Iwata S, et al. AP-1 transcriptional activity is regulated by a direct association between thioredoxin and Ref-1. Proc Natl Acad Sci U S A 1997;94:3633-8.
48. Zhou J, Schmid T, Frank R, Brune B. PI3K/Akt is required for heat shock proteins to protect hypoxia-inducible factor 1α from pVHL-independent degradation. J Biol Chem 2004;279:13506-13.
49. Isaacs JS, Jung YJ, Mimnaugh EG, et al. Hsp90 regulates a von Hippel Lindau-independent hypoxia-inducible factor-1α-degradative pathway. J Biol Chem 2002;277:29936-44.
50. Kallio PJ, Wilson WJ, O'Brien S, Makino Y, Poellinger L. Regulation of the hypoxia-inducible transcription factor 1α by the ubiquitin-proteasome pathway. J Biol Chem 1999;274:6519-25.
51. Shibata T, Yamada T, Ishii T, et al. Thioredoxin as a molecular target of cyclopentenone prostaglandins. J Biol Chem 2003;278:26046-54.